Neurochemical aspects on aging and diseases with cognitive impairment

Journal of Neuroscience Research

Volumn 27, Issue 4, 1990, Pages 541-547

  Gottfries, C G ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; gangliosides; neurochemical changes; neurotransmitter disturbances; white matter changes

Indexed keywords

AGING; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; GANGLIOSIDOSIS; HUMAN; HUMAN TISSUE; NEUROCHEMISTRY; PRIORITY JOURNAL; WHITE MATTER;

AGING; ALZHEIMER DISEASE; BRAIN CHEMISTRY; COGNITION DISORDERS; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0025634268     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.490270415     Document Type: Article

References (61)

1. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type
2. 3H] GBR‐12935 in Alzheimer's disease
3. Changes in biogenic amines and their metabolites in postmortem brains from patients with Alzheimer‐type dementia
4. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakow's disease
5. The cholinergic hypothesis in geriatric memory dysfunction
6. Corticotropin releasing factor‐like immunoreactivity in senile dementia of the Alzheimer type
7. Aging and the brain in etiology of dementia of Alzheimer's type
8. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations
9. Chemical pathology of the organic dementias. II. Quantitative estimation of cellular changes in post‐mortem brains
10. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer's dementia
11. Distribution of cerebral degeneration in Alzheimer's disease. A clino‐pathological study
12. Influence of age and lime interval between death and autopsy on dopamine and 3‐methoxytyramine levels in human basal ganglia
13. Neurotransmitter abnormalities in old age dementias
14. Neurotransmitter deficits in Alzheimer's disease
15. Monoamine metabolism in senile dementia of Alzheimer type
16. Cortical substance P like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type
17. Cortical somatostatin‐like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type
18. Reduced somatostatin‐like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia
19. Choline acetyltransferase somatostatin, and substance P in selected cases of Alzheimer's disease
20. Human memory and the cholinergic system
21. Senile dementia – a structural basis for etiological and therapeutic considerations
22. Selective inhibitors of MAO types A and B and their clinical usefulness
23. Markers of cholinergic dysfunction in Alzheimer disease
24. Platelet monoamine oxidase activity in megaloblastic anaemia
25. Alzheimer's disease. A critical review
26. Disturbance of the 5‐hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia
27. Review article. Neurochemical aspects of dementia disorders
28. The investigation of homovanillic acid in the human brain and its correlation to senile dementia
29. Lowered monoamine oxidase activity in brains from alcoholic suicides
30. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT)
31. Senile dementia — a “white matter” disease?
32. Alterations in L‐glutamate binding in Alzheimer's and Huntingtons disease
33. Review. Transmitter deficits in Alzheimer's disease. Critique: Gottfries CG, Rossor MN, Yates CM
34. Changes in the monoamine‐containing neurons of the human CNS in senile dementia
35. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle‐age form and age‐related continuum of pathological changes
36. Dopaminergic neuro‐transmitter systems in Alzheimer's disease and in Down's syndrome at middle‐age
37. 3H)imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders
38. Loss of nerve cells from the locus coeruleus in Alzheimer's disease is topipraphically arranged
39. Neurotransmitter metabolism in the aging brain
40. Aging, Alzheimer's disease and the cholinergic system of the basal forebrain
41. Platelet and brair monoamine oxidase in aging and in dementia of Al/heimer's type
42. Monoamine oxidase‐A and ‐B activity in the rat brain after hemitransection
43. Neurochemical basis of dementia of the Alzheimer type: Contribution of postmortem and antemortem studies
44. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease
45. Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography‐mass spectrometry
46. Abnormalities of vitamin B‐12 and other essential nutrients in dementia of Alzheimer type, and their clinical relevance
47. Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study
48. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type
49. Patterns of neuropeptide deficits in Alzheimer's disease
50. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age‐matched controls — a dose response study
51. Neurochemical changes in white matter of patients with Alzheimer's disease
52. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients
53. Neurotransmitter deficits in a nonmultiinfarct category of vascular dementia
54. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia ‐ diagnostic and pathogenetic aspects
55. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain
56. Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons